Patents by Inventor Paul Richard Gellert
Paul Richard Gellert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12364684Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament, and to processes for the preparation of said compositions.Type: GrantFiled: September 3, 2024Date of Patent: July 22, 2025Assignees: AstraZeneca AB, Array BioPharma, Inc.Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
-
Patent number: 12220403Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: GrantFiled: October 10, 2023Date of Patent: February 11, 2025Assignees: AstraZeneca AB, Array BioPharma, Inc.Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
-
Publication number: 20250000848Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament, and to processes for the preparation of said compositions.Type: ApplicationFiled: September 3, 2024Publication date: January 2, 2025Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20240423960Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament, and to processes for the preparation of said compositions.Type: ApplicationFiled: September 3, 2024Publication date: December 26, 2024Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20240041834Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: October 10, 2023Publication date: February 8, 2024Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20240041835Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: October 10, 2023Publication date: February 8, 2024Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Patent number: 11813246Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: GrantFiled: May 6, 2021Date of Patent: November 14, 2023Assignees: AstraZeneca AB, Array BioPharma, Inc.Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
-
Publication number: 20220087982Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: May 6, 2021Publication date: March 24, 2022Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20200179344Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: October 9, 2019Publication date: June 11, 2020Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20190030004Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: June 29, 2018Publication date: January 31, 2019Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20170056375Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: November 10, 2016Publication date: March 2, 2017Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20160030574Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: October 15, 2015Publication date: February 4, 2016Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
-
Publication number: 20120114750Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: November 10, 2011Publication date: May 10, 2012Applicants: ARRAY BIOPHARMA, INC, ASTRAZENECA ABInventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
-
Publication number: 20090246274Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.Type: ApplicationFiled: March 26, 2009Publication date: October 1, 2009Applicants: AstraZeneca AB, Array Biopharma, Inc.Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
-
Publication number: 20090186890Abstract: A pharmaceutical composition comprising 4-(3?-chloro-4?-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from solution.Type: ApplicationFiled: September 19, 2008Publication date: July 23, 2009Applicant: AstraZeneca ABInventors: Paul Richard Gellert, Marcel De Matas, Michael Davis Parker
-
Publication number: 20080248077Abstract: The present invention relates to slow release anastrozole formulations, more particularly to biodegradable polymers, typically a polylactide or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated, including microparticle formulations and monolithic implant formulations. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer.Type: ApplicationFiled: August 29, 2006Publication date: October 9, 2008Applicant: ASTRAZENECA ABInventors: Paul Richard Gellert, Balvinder Singh Matharu
-
Publication number: 20080206303Abstract: The present invention relates to slow release anastrozole formulations, more particularly to in situ gelling formulations comprising a polylactide polymer or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer, and processes for the preparation of said formulations.Type: ApplicationFiled: August 29, 2006Publication date: August 28, 2008Applicant: ASTRAZENECA ABInventors: Paul Richard Gellert, Balvinder Singh Matharu
-
Patent number: 7247491Abstract: A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of the peptide from the formulation. It can be used to discriminate between batches of formulations for quality control purposes and to discriminate between formulations, for example, having different drug loadings.Type: GrantFiled: October 5, 2001Date of Patent: July 24, 2007Assignee: AstraZeneca ABInventors: Brian Collingwood Clark, David Michael Cross, Paul Richard Gellert, Rodney Simon Kittlety
-
Publication number: 20040175402Abstract: The invention relates to a pharmaceutical formulation, preferably adapted for administration by injection, containing the compound 7a-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol and an antioxidant, more particularly to a formulation adapted for administration by injection containing the compound 7a-[9-(4,4,5,5,5-pentafluoropentyl-sulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol in solution in a ricinoleate vehicle which comprises an antioxidant.Type: ApplicationFiled: January 5, 2004Publication date: September 9, 2004Inventors: Paul Richard Gellert, Alison Margaret Potts
-
Publication number: 20040092452Abstract: A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of the peptide from the formulation. It can be used to discriminate between batches of formulations for quality control purposes and to discriminate between formulations, for example, having different drug loadings.Type: ApplicationFiled: April 8, 2003Publication date: May 13, 2004Inventors: Brian Collingwood Clark, David Michael Cross, Paul Richard Gellert, Rodney Simon Kittlety
